Form 4: ATAI Life Sciences Chief Medical Officer Reports Stock Transaction
SEC Form 4 Filing
Chief Medical Officer of ATAI Life Sciences, Kevin James Craig, reports the vesting and subsequent disposal of 20,000 common shares on March 14, 2025.
Summary
- On March 14, 2025, Kevin James Craig, the Chief Medical Officer of ATAI Life Sciences N.V., reported a transaction involving the vesting and disposal of 20,000 common shares.
- The transaction involved restricted stock units that vested on March 14, 2025, each representing a contingent right to receive one common share of the Issuer upon vesting and settlement.
- The reporting person directly owns 20,000 common shares following the reported transaction.
Sentiment
Score: 5
Explanation: This is a neutral regulatory filing, so the sentiment is neither positive nor negative.
Industry Context
This is a standard SEC Form 4 filing, which is common for corporate insiders reporting transactions in their company's stock. It provides transparency to the market regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| 03/14/2025 | Date of transaction: vesting and disposal of restricted stock units. |
| 03/19/2025 | Date of signature on the Form 4 filing. |
Keywords
ATAI Life Sciences, Chief Medical Officer, Kevin James Craig, Form 4, Stock Transaction, Restricted Stock Units, Common Shares, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.